🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Kilitch Drugs (India) Limited KILITCH NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://kilitch.com
Company Profile ↓
₹175.82
-18.74% 1Y
Mkt Cap₹614.69 Cr
P/E19.73
P/B2.20
52W High₹241.72
52W Low₹124.45
Book Value₹79.99
EPS (TTM)₹8.91

Company Overview

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products, including Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care products; herbal products for use in sore throat and prostate problems, as well as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical devices comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Further, it provides PH-7 which reduces acid content of the stomach; SRO kit for treating childhood diarrhea; 9-VIT for use in surgery, extensive burns, fractures, and other trauma; and HPURE for sore throat and cough. The company exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 42.4% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 19.2% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 19.7, below the sector median of 40.0.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.32.

Recent Developments

  • Mar 2026 Revenue of ₹235.47 Cr (+18.7% YoY); net profit ₹30.17 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +18.7%, earnings +13.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 19.2%, profit CAGR 42.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:19.25%
1 Year:18.74%

Compounded Profit Growth

5 Years:42.40%
1 Year:12.98%

Stock Price Performance

1 Year:-18.74%
6 Months:+4.30%
3 Months:+35.74%
1 Month:-4.49%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 44% of range
₹124.45 ₹241.72
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)42.59 · Neutral
Price Performance
1M-4.49%
3M+35.74%
6M+4.30%
1Y-18.74%
Valuation vs Sector

P/E of 19.73 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 19.2% over 5 years.
  • Profit CAGR of 42.4% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 27.3% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
19.73
Industry PE
39.97
Forward P/E
11.49
PEG Ratio
-
Book Value
₹79.99
Price to Book
2.20
P/S
2.67
EV/EBITDA
17.28
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
19.25%
Profit 5Y
42.40%
Revenue (YoY)
18.74%
Earnings (YoY)
12.98%

Profitability & Returns

ROCE
13.15%
ROE
10.79%
ROA
6.59%
Profit Margin
12.81%
Op Margin
14.00%
Gross Margin
46.43%
EPS (Latest Qtr)
₹4.24
EPS (TTM)
₹8.91

Balance Sheet & Liquidity

Debt/Equity
0.32
Quick Ratio
1.73
Current Ratio
1.83
Debt
₹88.71 Cr
Total Assets
₹457.75 Cr
Current Assets
₹222.20 Cr
Working Capital
₹100.60 Cr

Ownership

Promoter Holding
72.20%
Chg in Prom Hold
8.43%
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹614.69 Cr
Total Revenue (TTM)
₹235.47 Cr
EBITDA
₹47.84 Cr
Free Cash Flow
₹-75.55 Cr
Operating Cash Flow
₹23.96 Cr
Shares Outstanding
₹3.50 Cr
Gross Margin
46.43%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 KILITCH Kilitch Drugs (India) Limited NSEPHARMA 175.82 19.73 ₹614.69 Cr 0.00% 13.15% 10.79% 19.25% 42.40%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 45.00 Cr37.00 Cr41.00 Cr32.00 Cr45.00 Cr33.00 Cr47.00 Cr56.00 Cr61.23 Cr43.14 Cr48.92 Cr53.81 Cr89.60 Cr
Cost of Revenue --------28.70 Cr25.46 Cr26.36 Cr30.89 Cr44.15 Cr
Gross Profit --------32.53 Cr17.68 Cr22.56 Cr22.92 Cr45.45 Cr
Operating Expenses 39.00 Cr30.00 Cr33.00 Cr30.00 Cr38.00 Cr32.00 Cr41.00 Cr47.00 Cr18.78 Cr15.26 Cr18.38 Cr17.71 Cr24.29 Cr
Operating Income 5.00 Cr5.00 Cr8.00 Cr1.00 Cr6.00 Cr1.00 Cr5.00 Cr8.00 Cr13.75 Cr2.42 Cr4.18 Cr5.21 Cr21.16 Cr
EBITDA 6.00 Cr6.00 Cr9.00 Cr2.00 Cr7.00 Cr2.00 Cr6.00 Cr9.00 Cr16.29 Cr5.82 Cr11.70 Cr7.68 Cr22.64 Cr
Interest Expense 1.00 Cr2.00 Cr2.00 Cr2.00 Cr1.00 Cr2.00 Cr01.00 Cr1.60 Cr1.53 Cr1.44 Cr1.15 Cr1.44 Cr
Pretax Income 5.00 Cr5.00 Cr7.00 Cr3.00 Cr5.00 Cr2.00 Cr10.00 Cr8.00 Cr13.84 Cr3.45 Cr9.40 Cr5.60 Cr20.21 Cr
Tax Provision 2.15 Cr1.65 Cr1.75 Cr1.14 Cr1.55 Cr1.86 Cr1.70 Cr2.56 Cr3.63 Cr1.19 Cr1.36 Cr1.28 Cr5.33 Cr
Net Income 3.00 Cr3.00 Cr5.00 Cr2.00 Cr4.00 Cr09.00 Cr6.00 Cr10.40 Cr3.03 Cr8.19 Cr4.43 Cr14.52 Cr
Diluted EPS 1.050.991.350.831.030.382.461.706.470.922.481.254.24

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 19.00 Cr21.00 Cr27.00 Cr51.00 Cr82.00 Cr53.00 Cr68.00 Cr-138.86 Cr153.61 Cr198.32 Cr235.47 Cr
Cost of Revenue --------77.13 Cr80.47 Cr104.58 Cr126.13 Cr
Gross Profit --------61.72 Cr73.14 Cr93.74 Cr109.34 Cr
Operating Expenses 21.00 Cr25.00 Cr28.00 Cr45.00 Cr75.00 Cr53.00 Cr63.00 Cr-47.37 Cr52.05 Cr65.38 Cr76.37 Cr
Operating Income -4.00 Cr-14.00 Cr-11.00 Cr4.00 Cr5.00 Cr-2.00 Cr3.00 Cr-14.35 Cr21.08 Cr28.35 Cr32.98 Cr
EBITDA -2.00 Cr-4.00 Cr-1.00 Cr6.00 Cr7.00 Cr05.00 Cr-20.48 Cr28.63 Cr42.63 Cr47.84 Cr
Interest Expense 00001.00 Cr1.00 Cr1.00 Cr-4.92 Cr5.93 Cr5.04 Cr5.56 Cr
Pretax Income -1.00 Cr-12.00 Cr-9.00 Cr6.00 Cr9.00 Cr2.00 Cr5.00 Cr-12.01 Cr19.35 Cr34.47 Cr38.65 Cr
Tax Provision 70.00 L48.00 L45.00 L96.00 L4.95 Cr96.00 L1.35 Cr-3.73 Cr5.78 Cr9.53 Cr9.15 Cr
Net Income -0-11.00 Cr-9.00 Cr5.00 Cr4.00 Cr1.00 Cr4.00 Cr-10.45 Cr14.60 Cr26.70 Cr30.17 Cr
Diluted EPS -0.10-3.89-3.091.721.150.251.09-3.284.4916.608.91

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 127.00 Cr117.00 Cr113.00 Cr128.00 Cr144.00 Cr143.00 Cr203.00 Cr-219.52 Cr240.06 Cr312.78 Cr457.75 Cr
Current Assets --------126.40 Cr145.99 Cr173.92 Cr222.20 Cr
Cash & Equivalents --------19.79 Cr18.91 Cr9.75 Cr15.77 Cr
Inventory --------2.41 Cr5.58 Cr21.58 Cr11.52 Cr
Receivables --------54.29 Cr63.22 Cr84.74 Cr120.18 Cr
Total Liabilities --------68.94 Cr64.39 Cr112.33 Cr180.88 Cr
Current Liabilities --------68.87 Cr64.22 Cr84.31 Cr121.60 Cr
Long Term Debt ---------027.77 Cr58.60 Cr
Total Debt 001.00 Cr1.00 Cr9.00 Cr13.00 Cr15.00 Cr-22.19 Cr31.65 Cr49.42 Cr88.71 Cr
Total Equity 120.00 Cr108.00 Cr101.00 Cr112.00 Cr121.00 Cr118.00 Cr127.00 Cr-151.60 Cr176.29 Cr202.33 Cr279.65 Cr
Shares Outstanding --------3.18 Cr3.29 Cr3.29 Cr3.50 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -8.00 Cr17.00 Cr1.00 Cr1.00 Cr04.00 Cr46.00 Cr-2.59 Cr-1.53 Cr17.54 Cr23.96 Cr
Investing Cash Flow -31.00 Cr-20.00 Cr-2.00 Cr-4.00 Cr-14.00 Cr-10.00 Cr-38.00 Cr-7.92 Cr-8.16 Cr-39.95 Cr-100.44 Cr
Financing Cash Flow -00-06.00 Cr17.00 Cr1.00 Cr2.00 Cr--71.63 L8.81 Cr13.24 Cr82.45 Cr
Capital Expenditure -2.00 Cr-43.00 Cr-1.00 Cr-3.00 Cr-19.00 Cr-10.00 Cr-37.00 Cr--3.81 Cr-6.45 Cr-46.87 Cr-99.51 Cr
Free Cash Flow -10.00 Cr-26.00 Cr-0-2.00 Cr-19.00 Cr-6.00 Cr9.00 Cr--1.23 Cr-7.99 Cr-29.33 Cr-75.55 Cr
Net Change in Cash -39.00 Cr-2.00 Cr-02.00 Cr3.00 Cr-5.00 Cr10.00 Cr-9.78 Cr-88.45 L-9.16 Cr5.97 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------44.5%47.6%47.3%46.4%
Operating Margin % -21.1%-66.7%-40.7%7.8%6.1%-3.8%4.4%-10.3%13.7%14.3%14.0%
Net Margin % -0.0%-52.4%-33.3%9.8%4.9%1.9%5.9%-7.5%9.5%13.5%12.8%
ROE % -0.0%-10.2%-8.9%4.5%3.3%0.8%3.1%-6.9%8.3%13.2%10.8%
ROCE % --------9.5%12.0%12.4%9.8%

Shareholding Pattern

Insiders
72.20%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KILITCH

Google News Wed, 17 Jun 2026

Kilitch Starts New Nutraceutical Block; Shares Slip 0.5% - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNREd0R3lqS0tFSjFmLThrUG9FNDIyQ01uZGwwY0JVWnFoTUJCYmlzTlYzNlBhLWxMSVNIWVBOUGJzOFFhbm1rOW9FNVlXUmE1R0tUREItWXNqcEEwRUswWWV3X0RBMGN3NGY0elQ0R09aZnNkSnRUMHUyOWM2WlZfTi1LbGI0Q2xlbmlsRz…

Google News Fri, 15 May 2026

Kilitch Drugs (India) Ltd. Schedules Board Meeting on May 15, 2026 to Approve Q4FY26 Financial Results - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOSmF2Z2Q4UEoyaVMtRzJ5amVaMnFtUVNCZmRMWTJlbDhySkhLTFM3WU4zRXNOSGFRSW5DR25wWXNLbklUaEVSTl8zVzJ4bURWRE9JNk1EeWFIMW9ENVBxcUNvNlZtQjhnaHJBalZyZkQ0end2YVFwTEVnMTAxaDVPYjdKY3pPdlBrZnBic0…

Google News Mon, 18 May 2026

Kilitch Drugs Standalone March 2026 Net Sales at Rs 71.97 crore, up 27.82% Y-o-Y - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPSmZMV3o0UmNfZWVaU3RrNmFuNG82VF9lWEJCTDh6bUZRZmt5ZUMxY0xQcTZjZlE3dGR5MGlXU1VCS3dGS0FjbnNCYkplREk2VUplR1M4a3FqTDd1SEFUV0F3c3NZc2NjOG1MRU51LXF4Szgwbmx1TmxIOEVZc09rUkpWczcyMzdmeEpSUX…

Google News hu, 23 Oct 2025

Ace Investor Mukul Agrawal Picks Stake in this Smallcap Pharma Stock - Equitymaster

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxPdE9wM3JSYVJpLV9qQm0xWmoyT2lza3lOdDE3QUxndHFsVG9HTUhKWnRHMFRoNEpjbkFyQ0czMGhLenpLOEdpQlVIZnFvMkRKNGM0S1c3RkI2YVZ2X3R5SkdzdFNNS0JpZGxqZm1paG1nOW50YVltQ21mYVd3b2l2OEsxV2plMjZ4QWdUaV…

Google News Wed, 20 May 2026

Kilitch Drugs confirms no share encumbrance in FY26 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQUkpxQ1dtLWY2VE5lVWJxSXVqYkg3Z2dmWVYzSlpwSFV5SGdoTUo2NnA2ZV82SEFiQU1OWXlVZ19EbUhWSFluU0cxRzhGZVFhaklGWVVJVTd3eEFKdXBlTTZtNVBvMjlZOG9vcWRqQlQ4NnRZQ25GbG51QndtVHA0TmtTcl9idnEyVUtvak…

Google News Sat, 27 Jun 2026

AMANTA Stock Price and Chart — NSE:AMANTA - TradingView

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5lV2VCSDJIdzdKNXJXdUN2UXQ3cTNTWHhlNDJ3RTY3S1Noem9KemJfZU54SWU0Z0JCMnhFTS1pM3pfTnVZRldxN0tZQ19zXzNCSFdaS2pkeWR4SEk?oc=5" target="_blank">AMANTA Stock Price and Chart — NSE:AMANTA</a…

KILITCH — Frequently Asked Questions

What is the current share price of Kilitch Drugs (India) Limited (KILITCH)?

As of 2026-07-15 09:52 IST, Kilitch Drugs (India) Limited (KILITCH) trades at ₹175.82 on NSE. Its 52-week range is ₹124.45 to ₹241.72.

What is the market capitalisation of KILITCH?

Kilitch Drugs (India) Limited (KILITCH) has a market capitalisation of ₹614.69 Cr on NSE.

What is the P/E ratio of KILITCH?

KILITCH trades at a trailing price-to-earnings (P/E) ratio of 19.73. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 2.20.

What is the return on equity (ROE) of KILITCH?

KILITCH has a return on equity (ROE) of 10.79%. Its return on capital employed (ROCE) is 13.15%.

Is KILITCH a good stock to buy?

This page provides a data-driven analysis of Kilitch Drugs (India) Limited (KILITCH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space